doi:10.1038/s41591-024-03018-2 Abdul-Rahman T, Roy P, Ahmed FK, et al
There are currently almost 500 peptides recognized by the FDA as having therapeutic value to potentially treat various diseases, including [3]: Bone disorders Genetic disorders Cancer Infectious disease Cardiovascular problems Immune system Respiratory disorders Eye disorders Neurodegenerative problems Poor hormonal health Bone disorders Some of the most commonly used GHRH-promoting peptide drug products include tesamorelin, ipamorelin and sermorelin
is contracted via the University of Liverpool (no personal payment) to undertake consultancy for Altimmune, AstraZeneca, Boehringer Ingelheim, Cytoki, Eli Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern, Shionogi and Ysopia and declares personal honoraria/lecture fees from AstraZeneca, Boehringer Ingelheim, Medscape, Menarini, Napp, Novo Nordisk and Rhythm
PZ: Data curation, Writing original draft
It is simply how good medicine works, where approval follows evidence rather than the other way around
or in patients with chronic bronchitis where treatment periods were lengthy (1224 weeks) at doses of 400600 mg/day where NAC reduced the risk of exacerbations and improves symptoms in patients with chronic bronchitis compared with placebo (11 trials, 2,011 participants).(7) Clinical trial evidence for the use of NAC as an antioxidant in influenza and other acute viral respiratory tract infections is limited and relate to isolated small clinical trials